---
id: genital-mycoplasmas_327
category: organisms
tags: [Mycoplasma-genitalium, Ureaplasma, Mycoplasma-hominis, NGU, urethritis, macrolide-resistance, moxifloxacin]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Genital Mycoplasmas (M. genitalium, M. hominis, Ureaplasma)

**Q:** What is the treatment approach for M. genitalium given rising macrolide and quinolone resistance?

**A:**

**Mycoplasma genitalium:**

**Clinical Syndromes:**
- **Men**: **20-30% of NGU** (nongonococcal urethritis), proctitis
- **Women**: Cervicitis, PID, **2× risk** preterm delivery

**Major Problem: **Antimicrobial Resistance:**
- **Macrolide resistance**: **64%** in US (2017-2018); worldwide 51% (2016-2017)
- **Quinolone resistance**: **11.5%** in US
- **Doxycycline**: Only **30-40% effective** (monotherapy)
- **Azithromycin single dose**: **28% failure rate**

**Current Treatment (CDC 2021):**

**If Macrolide-Sensitive (or unknown):**
1. **Doxycycline 100 mg PO BID × 7 days**
THEN
2. **Azithromycin extended**: 1 g PO day 1, then 500 mg PO daily × 3 days (total 2.5 g over 4 days)

**If Macrolide-Resistant:**
1. **Doxycycline 100 mg PO BID × 7 days**
THEN
2. **Moxifloxacin 400 mg PO daily × 7 days**

**Key Treatment Principles:**
- **DO NOT use azithromycin 1 g single dose** (high failure + selects for resistance)
- **Doxycycline pretreatment** reduces bacterial load, may improve cure
- **Moxifloxacin cure rate declining** (was 100%, now ~89%)
- **Test-of-cure** at 3-4 weeks recommended (persistent infection common)

---

**Mycoplasma hominis:**

**Clinical Syndromes:**
- **Women**: Bacterial vaginosis, PID, post-cesarean fever
- **Men**: Uncommon (urethritis rare)
- **Neonates**: Sepsis, meningitis (rare)

**Treatment:**
- **Doxycycline** or **fluoroquinolones** (NO macrolide activity)
- Often part of polymicrobial BV treatment

---

**Ureaplasma urealyticum/parvum:**

**Clinical Syndromes:**
- **NGU** (controversial pathogen; often commensal)
- **Chorioamnionitis**, preterm birth
- **Neonatal**: Pneumonia, sepsis (especially in preterm infants)

**Treatment:**
- **Doxycycline** or **azithromycin**
- Treatment controversial for asymptomatic colonization

**Key Points:**
- **M. genitalium**: 20-30% NGU; **64% macrolide-resistant**
- **Dual therapy** required: Doxycycline × 7d THEN extended azithromycin OR moxifloxacin
- **Never use azithromycin 1 g single dose** for M. genitalium (selects resistance)
- **M. hominis/Ureaplasma**: Less common, respond to doxycycline

**Mnemonic - "M. genitalium = Most Genital NGU, Macrolide-resistant"**: 20-30% NGU, 64% macrolide resistance

**Pearl:** M. genitalium causes 20-30% of NGU with 64% macrolide resistance in US. NEVER use azithromycin single dose—use extended regimen (2.5 g total) or moxifloxacin after doxycycline pretreatment. Test-of-cure essential.

**Media:**

**Sources:** [CDC STI Guidelines M. genitalium 2024], [PMC4454211 - M. genitalium Resistance], [CDC EID Weighing Benefits/Harms 2022], [PMC3922211 - High Prevalence Resistance NGU]
